Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Simcha Therapeutics Holding Co. LLC

Headquarters: New Haven, CT, United States of America
Year Founded: 2018
Status: Private

BioCentury | Sep 4, 2024
Discovery & Translation

Immunoproteomics upstage genomics in I&I target discovery

Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Jan 30, 2024
Finance

Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast

Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 26, 2024
Product Development

Growing IL-18 field looks to enhance cell therapies via decoy evasion

As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
BioCentury | Dec 7, 2022
Product Development

ASH22 could be IL-18’s watershed moment

CAR T data at ASH could trigger more development in one of oncology’s less crowded cytokine spaces 
BioCentury | Aug 16, 2022
Management Tracks

Simcha hires CEO, expands research agreement

Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more
BioCentury | Jan 29, 2022
Product Development

Simcha pressure-testing engineered IL-18 with $40 million series B

Founded by Aaron Ring, Yale spinout is exploring its lead candidate’s potential as a cancer monotherapy while building out its management team
Items per page:
1 - 6 of 6